USA - NASDAQ:GCTK - US45824Q8042 - Common Stock
The current stock price of GCTK is 6.03 USD. In the past month the price decreased by -29.56%. In the past year, price decreased by -99.64%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.96 | 216.76B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.71 | 196.64B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.53 | 146.55B | ||
| SYK | STRYKER CORP | 27.16 | 136.74B | ||
| MDT | MEDTRONIC PLC | 16.35 | 115.96B | ||
| IDXX | IDEXX LABORATORIES INC | 57.11 | 57.62B | ||
| BDX | BECTON DICKINSON AND CO | 12.36 | 50.56B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.23 | 48.64B | ||
| RMD | RESMED INC | 24.77 | 35.79B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.47 | 34.52B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.91 | 27.03B | ||
| STE | STERIS PLC | 24.64 | 23.95B |
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
GLUCOTRACK INC
301 Rt 17 North, Suite 800
Rutherford NEW JERSEY US
Employees: 11
Phone: 197286757878
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
The current stock price of GCTK is 6.03 USD. The price decreased by -0.82% in the last trading session.
GCTK does not pay a dividend.
GCTK has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
GLUCOTRACK INC (GCTK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
The outstanding short interest for GLUCOTRACK INC (GCTK) is 7.23% of its float.
ChartMill assigns a technical rating of 2 / 10 to GCTK. When comparing the yearly performance of all stocks, GCTK is a bad performer in the overall market: 96.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to GCTK. The financial health of GCTK is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months GCTK reported a non-GAAP Earnings per Share(EPS) of -2312.58. The EPS increased by 20.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -262.19% | ||
| ROE | -389.1% | ||
| Debt/Equity | 0.03 |